

# Vincent H Tam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/991354/publications.pdf>

Version: 2024-02-01

104  
papers

4,640  
citations

147801

31  
h-index

106344

65  
g-index

108  
all docs

108  
docs citations

108  
times ranked

4699  
citing authors

#	ARTICLE	IF	CITATIONS
1	An integrated approach to evaluate different tetracycline derivatives for formulary decisions. American Journal of Health-System Pharmacy, 2022, 79, 467-471.	1.0	1
2	Hydrolytic activity of KPC-producing <i>Klebsiella pneumoniae</i> clinical isolates. Journal of Chemotherapy, 2022, 34, 345-346.	1.5	1
3	Discerning in vitro pharmacodynamics from OD measurements: A model-based approach. Computers and Chemical Engineering, 2022, 158, 107617.	3.8	6
4	In vitro activity of tigecycline and proteomic analysis of tigecycline adaptation strategies in clinical Enterococcus faecalis isolates from China. Journal of Global Antimicrobial Resistance, 2022, 30, 66-74.	2.2	2
5	Optimizing pharmacokinetics/pharmacodynamics of $\beta$ -lactam/ $\beta$ -lactamase inhibitor combinations against high inocula of ESBL-producing bacteria. Journal of Antimicrobial Chemotherapy, 2021, 76, 179-183.	3.0	18
6	Validation of Vancomycin Dosing Guidance During Transition of Care. Journal of Clinical Pharmacology, 2021, 61, 806-809.	2.0	0
7	Real life experience with ceftolozane/tazobactam therapy for <i>Pseudomonas aeruginosa</i> bacteremia. Journal of Chemotherapy, 2021, 33, 595-597.	1.5	3
8	Hepatoenteric recycling is a new disposition mechanism for orally administered phenolic drugs and phytochemicals in rats. ELife, 2021, 10, .	6.0	6
9	Simultaneous in vitro simulation of multiple antimicrobial agents with different elimination half-lives in a pre-clinical infection model. Computers and Chemical Engineering, 2021, 155, 107540.	3.8	4
10	Case Commentary: Novel Therapy for Multidrug-Resistant Acinetobacter baumannii Infection. Antimicrobial Agents and Chemotherapy, 2021, , AAC0199621.	3.2	0
11	Experimental Validation of a Mathematical Framework to Simulate Antibiotics with Distinct Half-Lives Concurrently in an In Vitro Model. Antibiotics, 2021, 10, 1256.	3.7	2
12	Clinical outcomes of cystic fibrosis patients with Pseudomonas aeruginosa bloodstream infection. Journal of Global Antimicrobial Resistance, 2021, , .	2.2	1
13	The impact of serum protein binding on bacterial killing of minocycline. Journal of Global Antimicrobial Resistance, 2020, 21, 252-254.	2.2	0
14	Optimizing Pharmacokinetics-Pharmacodynamics of Antimicrobial Management in Patients with Sepsis: A Review. Journal of Infectious Diseases, 2020, 222, S132-S141.	4.0	22
15	Performance of Population Pharmacokinetic Models in Predicting Polymyxin B Exposures. Microorganisms, 2020, 8, 1814.	3.6	4
16	New $\beta$ -Lactam- $\beta$ -Lactamase Inhibitor Combinations. Clinical Microbiology Reviews, 2020, 34, .	13.6	261
17	Prolonged Versus Intermittent Infusion of $\beta$ -Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. Clinical Pharmacokinetics, 2020, 59, 1237-1250.	3.5	18
18	Outpatient Subcutaneous Antimicrobial Therapy (OSCAT) as a Measure to Improve the Quality and Efficiency of Healthcare Delivery for Patients With Serious Bacterial Infections. Frontiers in Medicine, 2020, 7, 585658.	2.6	7

#	ARTICLE	IF	CITATIONS
19	MIC profiling of ceftazidime/avibactam against two carbapenemase-producing <i>Klebsiella pneumoniae</i> isolates. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 23, 385-387.	2.2	2
20	Local Tissue Response to Subcutaneous Administration of Ceftriaxone in an Animal Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	2
21	Characterization of Amikacin Drug Exposure and Nephrotoxicity in an Animal Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	9
22	A robust LC-MS/MS method for amikacin: application to cellular uptake and pharmacokinetic studies. <i>Bioanalysis</i> , 2020, 12, 445-454.	1.5	8
23	Toxicity in Patients. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 289-304.	1.6	13
24	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antimicrobial Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). <i>Pharmacotherapy</i> , 2019, 39, 10-39.	2.6	545
25	Generating Robust and Informative Nonclinical <i>In Vitro</i> and <i>In Vivo</i> Bacterial Infection Model Efficacy Data To Support Translation to Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	124
26	What the Clinical Microbiologist Should Know About Pharmacokinetics/Pharmacodynamics in the Era of Emerging Multidrug Resistance. <i>Clinics in Laboratory Medicine</i> , 2019, 39, 473-485.	1.4	12
27	Outcomes of empiric aminoglycoside monotherapy for <i>Pseudomonas aeruginosa</i> bacteremia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019, 93, 346-348.	1.8	8
28	Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum- $\beta$ -Lactamase-Producing <i>Enterobacteriaceae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	26
29	Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant <i>Pseudomonas aeruginosa</i> . <i>Microbiology and Immunology</i> , 2018, 62, 291-294.	1.4	7
30	Population Pharmacokinetics of Polymyxin B. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 534-538.	4.7	55
31	Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of <i>Klebsiella pneumoniae</i> in a tertiary care hospital. <i>Journal of Chemotherapy</i> , 2018, 30, 115-119.	1.5	7
32	<i>In Vivo</i> Resistance to Ceftolozane/Tazobactam in <i>Pseudomonas aeruginosa</i> Arising by AmpC- and Non-AmpC-Mediated Pathways. <i>Case Reports in Infectious Diseases</i> , 2018, 2018, 1-4.	0.5	18
33	Ertapenem in outpatient parenteral antimicrobial therapy for complicated urinary tract infections. <i>Journal of Chemotherapy</i> , 2017, 29, 25-29.	1.5	17
34	Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	26
35	Efficacy of Ceftaroline against Methicillin-Susceptible <i>Staphylococcus aureus</i> Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	17
36	The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized <i>Francisella tularensis</i> SCHU S4 Infection in BALB/c Mice and <i>Cynomolgus</i> Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	9

#	ARTICLE	IF	CITATIONS
37	Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	4
38	The complexity of minocycline serum protein binding. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1632-1634.	3.0	32
39	Determining $\beta$ -lactam exposure threshold to suppress resistance development in Gram-negative bacteria. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1421-1428.	3.0	72
40	Pharmacokinetics and Pharmacodynamics of Minocycline against <i>Acinetobacter baumannii</i> in a Neutropenic Murine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	19
41	Evaluation of Urinary KIM-1 for Prediction of Polymyxin B-Induced Nephrotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	8
42	Ceftolozane/tazobactam activity against meropenem-non-susceptible <i>Pseudomonas aeruginosa</i> bloodstream infection isolates. <i>Journal of Global Antimicrobial Resistance</i> , 2017, 11, 154-155.	2.2	5
43	Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	47
44	Dosing and Pharmacokinetics of Polymyxin B in Renal Insufficiency. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
45	An institutional review of antimicrobial stewardship interventions. <i>Journal of Global Antimicrobial Resistance</i> , 2016, 6, 75-77.	2.2	15
46	Comparative Pharmacokinetic Profiling of Different Polymyxin B Components. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6980-6982.	3.2	25
47	Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium: a multicentre, retrospective, cohort study: Table A1.. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3585-3587.	3.0	13
48	Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1029-1034.	3.2	35
49	Impact of hyperglycemia on outcomes of patients with <i>Pseudomonas aeruginosa</i> bacteremia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2016, 84, 155-158.	1.8	6
50	Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 727-730.	3.0	10
51	Quantitative determination of dopamine in human plasma by a highly sensitive LC-MS/MS assay: Application in preterm neonates. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 117, 227-231.	2.8	34
52	Modeling heterogeneous bacterial populations exposed to antibiotics: The logistic-dynamics case. <i>AICHE Journal</i> , 2015, 61, 2385-2393.	3.6	6
53	Analytical and Functional Determination of Polymyxin B Protein Binding in Serum. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7121-7123.	3.2	18
54	Cefepime free minimum concentration to minimum inhibitory concentration (fC <sub>min</sub> /MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 541-544.	2.5	58

#	ARTICLE	IF	CITATIONS
55	Risk factors for nephrotoxicity onset associated with polymyxin B therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1903-1907.	3.0	48
56	Kidney Injury Associated with Telavancin Dosing Regimen in an Animal Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2930-2933.	3.2	5
57	Assessment of Minocycline and Polymyxin B Combination against <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2720-2725.	3.2	56
58	<i>In Vitro</i> Ceftriaxone Susceptibility in Methicillin-Susceptible <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1370-1370.	3.2	12
59	Identification of optimal renal dosage adjustments for high-dose extended-infusion cefepime dosing regimens in hospitalized patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 877-881.	3.0	17
60	Reply to "Measuring Polymyxin Uptake by Renal Tubular Cells: Is BODIPY-Polymyxin B an Appropriate Probe?". <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6339-6339.	3.2	3
61	Predictive performance of pharmacokinetic models for outpatients receiving vancomycin continuous infusion. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 197-199.	2.5	3
62	An evaluation of multiple phenotypic screening methods for <i>Klebsiella pneumoniae</i> carbapenemase (KPC)-producing Enterobacteriaceae. <i>Journal of Infection and Chemotherapy</i> , 2014, 20, 224-227.	1.7	9
63	Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2517-2521.	3.0	19
64	Uptake of Polymyxin B into Renal Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4200-4202.	3.2	47
65	Validation of a Model To Predict the Risk of Nephrotoxicity in Patients Receiving Colistin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6946-6948.	3.2	15
66	Development and validation of a highly sensitive LC-MS/MS assay for the quantification of arginine vasopressin in human plasma and urine: Application in preterm neonates and child. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 99, 67-73.	2.8	17
67	Mathematical Model To Quantify the Effects of Risk Factors on Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5239-5244.	3.2	1
68	<i>Pseudomonas aeruginosa</i> treatment and transmission reduction. <i>Expert Review of Anti-Infective Therapy</i> , 2013, 11, 831-837.	4.4	2
69	<i>In Vitro</i> Pharmacodynamics of AZD5206 against <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1062-1064.	3.2	5
70	A model to predict mortality following <i>Pseudomonas aeruginosa</i> bacteremia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2012, 72, 97-102.	1.8	23
71	Emergence of KPC-producing <i>Klebsiella pneumoniae</i> in Texas. <i>Diagnostic Microbiology and Infectious Disease</i> , 2011, 69, 234-235.	1.8	10
72	Effect of multidrug resistance-conferring mutations on the fitness and virulence of <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1311-1317.	3.0	49

#	ARTICLE	IF	CITATIONS
73	A Novel Approach to Pharmacodynamic Assessment of Antimicrobial Agents: New Insights to Dosing Regimen Design. <i>PLoS Computational Biology</i> , 2011, 7, e1001043.	3.2	32
74	Quantitative Assessment of Combination Antimicrobial Therapy against Multidrug-Resistant Bacteria in a Murine Pneumonia Model. <i>Journal of Infectious Diseases</i> , 2010, 201, 889-897.	4.0	25
75	Impact of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Bacteremia on Patient Outcomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3717-3722.	3.2	138
76	Prevalence, Resistance Mechanisms, and Susceptibility of Multidrug-Resistant Bloodstream Isolates of <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1160-1164.	3.2	122
77	Impact of multidrug-resistant <i>Pseudomonas aeruginosa</i> infection on patient outcomes. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 441-451.	1.4	336
78	Variability of polymyxin B major components in commercial formulations. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 308-310.	2.5	58
79	Impact of AmpC overexpression on outcomes of patients with <i>Pseudomonas aeruginosa</i> bacteremia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 63, 279-285.	1.8	15
80	Killing of <i>Escherichia coli</i> by $\beta$ -lactams at different inocula. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 166-171.	1.8	19
81	In vivo dynamics of carbapenem-resistant <i>Pseudomonas aeruginosa</i> selection after suboptimal dosing. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 427-433.	1.8	17
82	Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. <i>International Journal of Antimicrobial Agents</i> , 2009, 34, 570-574.	2.5	58
83	Pharmacokinetic/pharmacodynamic antimicrobial individualization and optimization strategies. <i>Current Infectious Disease Reports</i> , 2008, 10, 9-13.	3.0	0
84	Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008, 60, 163-167.	1.8	77
85	Polymyxin B: a new strategy for multidrug-resistant Gram-negative organisms. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 661-668.	4.1	41
86	Quantitative Assessment of Combination Antimicrobial Therapy against Multidrug-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2898-2904.	3.2	31
87	Outcomes of Bacteremia due to <i>Pseudomonas aeruginosa</i> with Reduced Susceptibility to Piperacillin-Tazobactam: Implications on the Appropriateness of the Resistance Breakpoint. <i>Clinical Infectious Diseases</i> , 2008, 46, 862-867.	5.8	106
88	Pharmacodynamic Modeling of Aminoglycosides against <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> : Identifying Dosing Regimens To Suppress Resistance Development. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3987-3993.	3.2	52
89	Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 168-171.	3.0	146
90	Independent predictors for mortality in patients with positive <i>Stenotrophomonas maltophilia</i> cultures. <i>Annals of the Academy of Medicine, Singapore</i> , 2008, 37, 826-30.	0.4	14

#	ARTICLE	IF	CITATIONS
91	The Relationship between Quinolone Exposures and Resistance Amplification Is Characterized by an Inverted U: a New Paradigm for Optimizing Pharmacodynamics To Counterselect Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 744-747.	3.2	124
92	Mathematical modelling response of <i>Pseudomonas aeruginosa</i> to meropenem. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1302-1309.	3.0	28
93	Prevalence, mechanisms, and risk factors of carbapenem resistance in bloodstream isolates of <i>Pseudomonas aeruginosa</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 309-314.	1.8	39
94	Polymyxin B: similarities to and differences from colistin (polymyxin E). <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 811-821.	4.4	142
95	Mathematical formulation of additivity for antimicrobial agents. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 55, 319-325.	1.8	36
96	Comparative performance of different stochastic methods to simulate drug exposure and variability in a population. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006, 56, 185-188.	1.8	1
97	Impact of Sample Size on the Performance of Multiple-Model Pharmacokinetic Simulations. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 3950-3952.	3.2	31
98	An integrated pharmacoeconomic approach to antimicrobial formulary decision-making. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 735-739.	1.0	7
99	Comparative Pharmacodynamics of Gentamicin against <i>Staphylococcus aureus</i> and <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2626-2631.	3.2	98
100	Optimization of Meropenem Minimum Concentration/MIC Ratio To Suppress In Vitro Resistance of <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4920-4927.	3.2	178
101	Modelling time-kill studies to discern the pharmacodynamics of meropenem. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 699-706.	3.0	110
102	Pharmacodynamics of Polymyxin B against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3624-3630.	3.2	198
103	Comparison of $\beta$ -lactams in counter-selecting resistance of <i>Pseudomonas aeruginosa</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2005, 52, 145-151.	1.8	23
104	Novel Approach to Characterization of Combined Pharmacodynamic Effects of Antimicrobial Agents. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4315-4321.	3.2	34